Table 1.

Percentages of phenotypes observed after microinjection of small GTPase proteins into Swiss 3T3 cells

Treatment	Time, min	Filopodia	Lamellipodia
Control	15	13.8  ±  2.5	0.7  ±  0.7
RalA (1.4 mg/ml)	5	54.8  ±  1.6	0.0  ±  0.0
RalA	15	68.6  ±  3.2	0.3  ±  0.3
RalA	60	46.1  ±  4.0	1.3  ±  1.3
RalA	90	27.3  ±  1.0	4.3  ±  1.1
V23RalA (0.4 mg/ml)	15	62.2  ±  8.2	1.1  ±  1.1
V12Cdc42 (1.0 mg/ml)	5	60.0  ±  2.6	1.4  ±  1.4
V12Cdc42	15	32.9  ±  7.3	29.2  ±  4.6
V12Cdc42	60	26.3  ±  1.2	39.3  ±  6.0
V12Cdc42	90	3.6  ±  2.6	64.7  ±  7.5
N28RalA (1.4 mg/ml)	5	16.4  ±  0.4	0.0  ±  0.0
N17Cdc42 (2.0 mg/ml)	15	16.7  ±  0.0	0.0  ±  0.0
V23RalA (0.4 mg/ml) + N17Cdc42 (2.0 mg/ml)	15	60.5  ±  1.4	2.4  ±  0.9
V12Cdc42 (0.46 mg/ml) + N28RalA (1.6 mg/ml)	5	15.2  ±  4.9	1.3  ±  1.3
V12Cdc42 + N28RalA	90	15.3  ±  2.1	62.9  ±  6.5
V23RalA (0.7 mg/ml) + GST (0.82 mg/ml)	15	51.0  ±  1.8	11.4  ±  2.3
V23RalA (0.7 mg/ml) + GST-filamin 1	15	24.1  ±  6.4	8.0  ±  3.1
(2554–2647) (1.2 mg/ml)

The percentages of filopod- or lamellipod-positive cells were calculated and data are expressed as the mean ± SE. The GST-filamin 1 fragment did not affect the actions of 0.8 mg/ml Rac or 0.8 mg/ml RhoA, which produced respectively lamellipodia or stress fibers in 60–70% of injected cells.